Rob Mitchell

Chief Executive Officer at Caldera Health Ltd.

Rob Mitchell

Rob Mitchell

Chief Executive Officer at Caldera Health Ltd.

Biography

Presently, Rob Mitchell is Chief Executive Officer of Caldera Health Ltd. In the past Mr. Mitchell held the position of Head-Asia Pacific at The Medicines Co.

Overview
Career Highlights

Caldera Health Ltd.

RelSci Relationships

289

Relationships
RelSci Relationships are individuals Rob Mitchell likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founder at Caldera Health Ltd.

Relationship likelihood: Strong

Managing Director & Director at Caldera Health Ltd.

Relationship likelihood: Strong

Co-Founder at Caldera Health Ltd.

Relationship likelihood: Strong

Chief Technology Officer at Caldera Health Ltd.

Relationship likelihood: Strong

Director-Research & Development at Caldera Health Ltd.

Relationship likelihood: Strong

Chief Scientist at Caldera Health Ltd.

Relationship likelihood: Strong

Clinical Study Manager at Caldera Health Ltd.

Relationship likelihood: Strong

Laboratory Manager & Scientist at Caldera Health Ltd.

Relationship likelihood: Strong

Finance Manager at Caldera Health Ltd.

Relationship likelihood: Strong

Senior Scientist at Caldera Health Ltd.

Relationship likelihood: Strong

Paths to Rob Mitchell
Potential Connections via
Relationship Science
You
Rob Mitchell
Chief Executive Officer at Caldera Health Ltd.
Education
Post-Graduate in Business, Marketing

AN INTERNATIONAL UNIVERSITY, RECOGNIZED FOR EXCELLENCE IN TEACHING, LEARNING, RESEARCH, AND CONTRIBUTIONS TO KNOWLEDGE TO SERVE LOCAL, NATIONAL AND INTERNATIONAL COMMUNITIES.

Career History
Chief Executive Officer
Current

Caldera Health Ltd. designs and develops medical equipment for detection of prostate cancer. The firm is seeking new diagnostic biomarkers for to detect early onset of prostate cancer and the likely course of disease. The company was founded by Jim Watson in 2009 and is headquartered in Auckland, New Zealand

Head-Asia Pacific
2011 - Prior

The Medicines Co We are a global pharmaceutical company focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. In the United States, we have three marketed products, Angiomax® (bivalirudin) for Injection, Cleviprex® (clevidipine) Injectable Emulsion, and Argatroban Injection, 50 mg per 50 mL†. We also have a pipeline of acute and intensive care hospital products in development, including three late-stage development product candidates, cangrelor, oritavancin and MDCO-157, and two early stage development product candidates, MDCO-2010 and MDCO-216. We believe that Angiomax, Cleviprex and our products in development possess favorable attributes that can satisfy unmet medical needs in the acute | intensive care hospital product market and offer, or, in the case of our products in development, have the potential to offer, improved performance to hospital businesses. The Company is publicly traded on the Nasdaq exchange under the ticker symbol MDCO. It was founded in 1996 and employs approximately 425 professionals.

General Manager
Prior

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Other Affiliations
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Rob Mitchell. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Rob Mitchell's profile does not indicate a business or promotional relationship of any kind between RelSci and Rob Mitchell.